Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study

Table 1 Patient characteristics of patients subject to BAL

	Age	ANA^a	SSc-associated antibodies^b	SSc-subtype	mRSS	%pVC^c	%pDLCO^d	Disease duration (months)^e	Sex	BAL cellularity, distribution (%)
	Age	ANA^a	SSc-associated antibodies^b	SSc-subtype	mRSS	%pVC^c	%pDLCO^d	Disease duration (months)^e	Sex	Lymphocytes	Neutrophils	Eosinophils	Macrophages	Other
Pat 1	28	ANA positive. Nucleolar	Anti-PM/Scl	lcSSc	2	66	61	11	F	0	0	0	96	4
Pat 2	55	ANA positive. Centromere	Anti-Ro52 ACA	lcSSc	2	88	76	108	F	9	0	0	75	16
Pat 3	59	ANA positive. Speckled	Anti-Ro52 Anti-Ro60 Anti-La/SSB Anti-U1RNP	lcSSc	4	101	80	N/A	M	8	42	2	29	19
Pat 4	40	ANA positive. Nucleolar	Anti-PM/Scl Anti-U1RNP	dcSSc	6	80	42	24	M	13	10	5	57	15
Pat 5	55	ANA positive. Speckled	Anti-Scl-70	dcSSc	19	56	32	2	M	9	4	5	74	8
Pat 6	68	ANA positive. Speckled and homogenous	-	lcSSc	5	73	57	72	F	8	4	1	78	9
Pat 7	68	ANA positive. Speckled	Anti-Scl-70	lcSSc	9	57	45	50	F	12	20	0	54	14
Pat 8	68	ANA positive. Nucleolar	-	lcSSc	3	85*	88*	15	F	26	23	4	39	8
Pat 9	58	ANA positive. Nucleolar	Anti-Ro52 Anti-PM/Scl	dcSSc	34	62	28	11	M	7	6	7	57	23
Pat 10	56	ANA positive. Nucleolar	Anti-PM/Scl	dcSSc	20	70	81	40	F	9	28	2	35	26
Pat 11	67	ANA-negative	-	dcSSc	10	56	39	8	F	16	6	5	70	3
Pat 12	50	ANA positive. Homogenous	Anti-Ro52	dcSSc	15	93	62	12	F	5	1	1	93	0
Pat 13	70	ANA positive, pattern could not be defined	ACA	lcSSc	2	122	69	6	F	8	5	1	86	0
Pat 14	57	ANA negative	Anti-Ro60	dcSSc	19	95	62	36	M	6	5	4	84	1
Pat 15	46	ANA negative	Anti-Ro52	dcSSc	9	63	53	10	M	7	0	4	84	5

^aImmunoflourescence pattern
^bthe following autoantibodies were tested Anti-Ro52 Anti-Ro60 Anti-SSB/La, Anti-U1RNP Anti-PM/Scl, ACA (anti-centromere) Anti-Scl-70 (anti-topoisomerase)
^c% predicted vital capacity
^d% predicted diffusing capacity for carbon monoxide
^eSince first first non-Raynaud’s phenomenon manifestation of SSc (months)

ISSN: 1478-6362